Titan Pharmaceuticals, Inc. (OTC:TTNP) Gets Out of Tangle, Shoots Up Again
After a series of jolts, Titan Pharmaceuticals, Inc. (OTC:TTNP) returns with a new promise, awaiting an FDA verdict on April 30th. The mix of positive and negative signals should keep this ticker high on investors’ list, and we may expect to see a recovery after a few frantic days when the FDA put up a less than favorable estimation of the company’s newest treatment. 
A new review by Seeking Alpha advertises TTNP as underpriced, even after adding more than 35% to $1.67. The company has taken hold not only of a medical niche, but of a social need- opioid addictions, especially to heroine, and this may help the ongoing approval procedure since the FDA has a preferential policy for drugs addressing such problems.
The most recent financial data from TTNP show an active business, though one burdened by debt due to the development process for new drugs and therapies. Currently, the company can rely on the following resources:
- $18 million cash
- $21 million total current assets
- $47 million total liabilities
- $7.1 million total revenues
- $15.1 million net loss
The latest 8-K from the company is nothing else but a reiteration of the preliminary vote of FDA experts last Thursday. Then, the panel voted 10 to 4 in favor of allowing the implant therapy against addictions. The agency usually heeds those votes, though it is not obliged to do so in every case. On the negative size, the matchstick-sized implant has caused concern among the medics, and there are glitches around the right dose.
While the buying in the past days has not completely compensated the record selling, the stock’s rebounce has been fierce and gives a hope for the days ahead. But last week also gives an example of the fragile situation of pharmaceutical companies, with their stock depending much on sentiment and being harmed severely by any news with a negative slant.
Still, it is up to the discretion of separate investors if they would join the TTNP trend and take the losses as well as the gains until April 30th, when the final decision of the FDA should be announced.
